Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C BORDEN

Showing results (321-330 of 327) with videos related to

Pageof 33
Sort By:
You have reached the last page of results.This site can display upto 327 results.
Molecular Cancer Therapeutics|June 16, 2005
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumorsDavid E Weng, Paul A Masci, Susan F Radka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Journal of Orthopaedic Trauma|September 26, 2024
Incidence of Ipsilateral Femoral Neck and Shaft Fractures in Pediatric and Adolescent PatientsTimothy C Borden, Layla A Haidar, Rohini M Vanodia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Soft tissue sarcomas of adults: state of the translational scienceErnest C Borden, Laurence H Baker, Robert S Bell, et al.
Journal for Immunotherapy of Cancer|April 18, 2020
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, et al.
Pageof 33

Showing results (321-330 of 327) with videos related to

Sort By:
Pageof 33
You have reached the last page of results.This site can display upto 327 results.
Molecular Cancer Therapeutics|June 16, 2005
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumorsDavid E Weng, Paul A Masci, Susan F Radka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Journal of Orthopaedic Trauma|September 26, 2024
Incidence of Ipsilateral Femoral Neck and Shaft Fractures in Pediatric and Adolescent PatientsTimothy C Borden, Layla A Haidar, Rohini M Vanodia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Soft tissue sarcomas of adults: state of the translational scienceErnest C Borden, Laurence H Baker, Robert S Bell, et al.
Journal for Immunotherapy of Cancer|April 18, 2020
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, et al.
Pageof 33